8-K Announcements
6Material company update
Apr 13, 2026·SEC
Material company update
Feb 3, 2026·SEC
Material company update
Jan 12, 2026·SEC
Replimune Group, Inc.(REPL)Earnings, Financials & Key Ratios
REPL•NASDAQ
$3.42
$272M mkt cap·Price updated May 6, 2026
AboutReplimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Show more
- Revenue$0
- EBITDA-$256M-11.3%
- Net Income-$247M-14.6%
- EPS (Diluted)-3.07+5.2%
- ROE-62.58%-34.8%
- ROIC-51.85%-24.5%
- Debt/Equity0.18-9.6%
- Interest Coverage-33.15+6.0%
REPL Key Insights
Replimune Group, Inc. (REPL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.7x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Shares diluted 21.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
REPL Price & Volume
Replimune Group, Inc. (REPL) stock price & volume — 10-year historical chart
Loading chart...
REPL Growth Metrics
Replimune Group, Inc. (REPL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-37.95%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-13.65%
Return on Capital
10 Years-37.31%
5 Years-36.19%
3 Years-44.6%
Last Year-55.89%
REPL Recent Earnings
Replimune Group, Inc. (REPL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q1 2026Latest
Feb 3, 2026EPS
$0.77
Est $0.77
-0.2%
Revenue
—
Est $428,571
Q4 2025
Nov 6, 2025EPS
$0.90
Est $0.87
-3.4%
Revenue
—
Est $714,286
Q3 2025
Aug 7, 2025EPS
$0.95
Est $0.83
-14.5%
Revenue
—
Est $500,000
Q2 2025
May 22, 2025EPS
$0.82
Est $0.75
-9.3%
Revenue
$1M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 3, 2026 | $0.77vs $0.77-0.2% | —vs $428,571 |
| Q4 2025 | Nov 6, 2025 | $0.90vs $0.87-3.4% | —vs $714,286 |
| Q3 2025 | Aug 7, 2025 | $0.95vs $0.83-14.5% | —vs $500,000 |
| Q2 2025 | May 22, 2025 | $0.82vs $0.75-9.3% | $1M |
Based on last 12 quarters of dataView full earnings history →
REPL Peer Comparison
Replimune Group, Inc. (REPL) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AMGN | 178.7B | 331.11 | 23.27 | 9.92% | 20.95% | 89.41% | 6.31 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 CGEN | 247.13M | 2.76 | -17.25 | -16.72% | -5.77% | -71.54% | 0.05 | |
 IOVA | 1.68B | 4.09 | -3.75 | 60.6% | -148.38% | -55.97% | 0.07 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 | |
 ADCT | 490.96M | 3.86 | -3.45 | 14.85% | -173.02% |
Compare REPL vs Peers
Replimune Group, Inc. (REPL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
REPL Income Statement
Replimune Group, Inc. (REPL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 122K | 109K | 148K | 0 | 4.14M | 4.58M | 0 | 0 | 0 | 4.14M |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -122K▲ 0% | -109K▲ 10.7% | -148K▼ 35.8% | 0▲ 100.0% | -4.14M▲ 0% | -4.58M▼ 10.5% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -4.14M▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 10.66% | -35.78% | 100% | - | -10.53% | 100% | - | - | - |
| Operating Expenses | 8.21M | 16.96M | 28.42M | 56.2M | 78.62M | 116.91M | 177.08M | 234.77M | 261.63M | 324.3M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.71M | 5.71M | 8.77M | 17.44M | 21.13M | 36.26M | 0 | 0 | 0 | 69.65M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 6.94M | 13.52M | 22.17M | 38.76M | 57.49M | 80.64M | 126.53M | 174.96M | 189.45M | 223.39M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 626K | -2.06M | 451K | 0 | 0 | 0 | 50.55M | 59.81M | 72.18M | 0 |
| Operating Income | -9.65M▲ 0% | -19.23M▼ 99.3% | -30.95M▼ 60.9% | -56.2M▼ 81.6% | -82.76M▼ 47.3% | -121.48M▼ 46.8% | -177.08M▼ 45.8% | -234.77M▼ 32.6% | -261.63M▼ 11.4% | -326.46M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -99.33% | -60.93% | -81.6% | -47.27% | -46.79% | -45.76% | -32.58% | -11.44% | - |
| EBITDA | -9.53M | -19.12M | -30.8M | -55.66M | -78.62M | -116.91M | -174.63M | -229.69M | -255.7M | -322.85M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -100.73% | -61.08% | -80.74% | -41.24% | -48.7% | -49.38% | -31.53% | -11.32% | -37.05% |
| D&A (Non-Cash Add-back) | 122K | 109K | 148K | 533K | 4.14M | 4.58M | 2.45M | 5.08M | 5.93M | 3.61M |
| EBIT | -8.21M | -19.7M | -30.83M | -53.11M | -80.62M | -118.98M | -174.17M | -232.85M | -259.85M | -314.99M |
| Net Interest Income | 0 | 0 | 2.58M | 505K | -2.14M | -1.83M | 5.85M | 16.7M | 13.23M | 2.24M |
| Interest Income | 25K | 288K | 2.58M | 2.42M | 916K | 390K | 10.01M | 23.36M | 21.12M | 8.72M |
| Interest Expense | 0 | 0 | 0 | 1.92M | 3.06M | 2.22M | 4.16M | 6.66M | 7.89M | 6.48M |
| Other Income/Expense | 1.94M | -473K | 112K | 3.57M | -915K | 278K | 3.08M | 19.39M | 14.8M | 10.64M |
| Pretax Income | -7.7M▲ 0% | -19.7M▼ 155.7% | -30.83M▼ 56.5% | -52.63M▼ 70.7% | -83.68M▼ 59.0% | -121.21M▼ 44.8% | -174M▼ 43.6% | -215.39M▼ 23.8% | -246.83M▼ 14.6% | -315.82M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | -2.81M | -3.17M | 288K | 408K | 468K | -969K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 3.35% | 2.62% | -0.17% | -0.19% | -0.19% | 0.31% |
| Net Income | -7.7M▲ 0% | -19.7M▼ 155.7% | -30.83M▼ 56.5% | -52.63M▼ 70.7% | -80.87M▼ 53.7% | -118.04M▼ 46.0% | -174.28M▼ 47.7% | -215.79M▼ 23.8% | -247.3M▼ 14.6% | -314.85M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -155.74% | -56.5% | -70.67% | -53.67% | -45.96% | -47.65% | -23.82% | -14.6% | -37.95% |
| Net Income (Continuing) | -7.7M | -19.7M | -30.83M | -52.63M | -80.87M | -118.04M | -174.28M | -215.79M | -247.3M | -314.85M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.25▲ 0% | -0.64▼ 156.0% | -1.33▼ 107.8% | -1.54▼ 15.8% | -1.75▼ 13.6% | -2.26▼ 29.1% | -2.99▼ 32.3% | -3.24▼ 8.4% | -3.07▲ 5.2% | -3.42▲ 0% |
| EPS Growth % | - | -156% | -107.81% | -15.79% | -13.64% | -29.14% | -32.3% | -8.36% | 5.25% | -13.65% |
| EPS (Basic) | -0.36 | -0.64 | -1.33 | -1.54 | -1.75 | -2.26 | -2.99 | -3.24 | -3.07 | - |
| Diluted Shares Outstanding | 30.84M | 30.84M | 23.2M | 34.26M | 46.25M | 52.21M | 58.21M | 66.57M | 80.56M | 92.19M |
| Basic Shares Outstanding | 21.51M | 30.84M | 23.2M | 34.26M | 46.25M | 52.21M | 58.21M | 66.57M | 80.56M | 92.19M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
REPL Balance Sheet
Replimune Group, Inc. (REPL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 22.4M | 64.7M | 140.98M | 174.25M | 483.75M | 403.98M | 592.6M | 433.67M | 495.88M | 280.35M |
| Cash & Short-Term Investments | 20.59M | 61.55M | 134.81M | 168.56M | 476.3M | 395.65M | 583.39M | 420.67M | 483.8M | 269.14M |
| Cash Only | 20.59M | 17.58M | 25.7M | 59.5M | 182.52M | 105.95M | 146.59M | 74.46M | 111.12M | 122.95M |
| Short-Term Investments | 0 | 43.97M | 109.11M | 109.06M | 293.78M | 289.71M | 436.8M | 346.21M | 372.69M | 146.19M |
| Accounts Receivable | 1.41M | 2.39M | 2.47M | 2.96M | 2.95M | 3.06M | 2.94M | 4.92M | 3.73M | 2.96M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 6.28M | 8.08M | 0 | 8.26M |
| Total Non-Current Assets | 417K | 448K | 13.35M | 59.85M | 59.35M | 57.22M | 53.99M | 54.05M | 55.45M | 53.24M |
| Property, Plant & Equipment | 342K | 370K | 12.16M | 58.21M | 57.72M | 55.58M | 52.35M | 52.35M | 52.55M | 50.33M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 75K | 78K | 1.19M | 0 | 0 | 0 | 0 | 0 | 0 | 3.84M |
| Other Non-Current Assets | 0 | 0 | 0 | 1.64M | 1.64M | 1.64M | 1.64M | 1.7M | 2.9M | 9.01M |
| Total Assets | 22.82M▲ 0% | 65.15M▲ 185.5% | 154.33M▲ 136.9% | 234.1M▲ 51.7% | 543.1M▲ 132.0% | 461.19M▼ 15.1% | 646.59M▲ 40.2% | 487.72M▼ 24.6% | 551.33M▲ 13.0% | 333.59M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 185.51% | 136.87% | 51.69% | 132% | -15.08% | 40.2% | -24.57% | 13.04% | -65.76% |
| Total Current Liabilities | 1.99M | 5.16M | 9.88M | 11.87M | 14.55M | 20.76M | 33.83M | 40.44M | 62.36M | 50.09M |
| Accounts Payable | 323K | 1.99M | 7.08M | 3.43M | 2.35M | 3.73M | 5.36M | 2.58M | 12.46M | 5.65M |
| Days Payables Outstanding | 966.35 | 6.67K | 17.47K | - | 207.68 | 297.74 | - | - | - | 882.22 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.08M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 59K | 179K | 297K | 2.37M | 4.47M | 6.89M | 12.9M | 17.24M | 6.07M | 40.37M |
| Current Ratio | 11.29x | 12.53x | 14.26x | 14.68x | 33.25x | 19.46x | 17.52x | 10.72x | 7.95x | 7.95x |
| Quick Ratio | 11.29x | 12.53x | 14.26x | 14.68x | 33.25x | 19.46x | 17.52x | 10.72x | 7.95x | 7.95x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 32.35M | 88.06M | 6.58M | 38.51M | 29.82M | 29.21M | 57.47M | 72.78M | 73.12M | 72.96M |
| Long-Term Debt | 0 | 0 | 0 | 9.8M | 0 | 0 | 28.65M | 44.81M | 46.38M | 50.14M |
| Capital Lease Obligations | 0 | 0 | 0 | 28.7M | 29.82M | 29.21M | 28.35M | 27.18M | 25.8M | 101.01M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 32.35M | 88.06M | 6.58M | 0 | 0 | 0 | 472K | 786K | 941K | 1M |
| Total Liabilities | 34.33M | 93.22M | 16.47M | 50.38M | 44.37M | 49.96M | 91.3M | 113.21M | 135.49M | 123.05M |
| Total Debt | 0 | 0 | 6.56M | 41.79M | 33.28M | 32.84M | 60.76M | 75.87M | 76.17M | 78.86M |
| Net Debt | -20.59M | -17.58M | -19.14M | -17.71M | -149.24M | -73.11M | -85.83M | 1.41M | -34.95M | -94.23M |
| Debt / Equity | - | - | 0.05x | 0.23x | 0.07x | 0.08x | 0.11x | 0.20x | 0.18x | 0.18x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.24x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.29x |
| Interest Coverage | - | - | - | -29.29x | -27.05x | -54.65x | -42.57x | -35.25x | -33.15x | -48.62x |
| Total Equity | -11.52M▲ 0% | -28.07M▼ 143.8% | 137.86M▲ 591.2% | 183.72M▲ 33.3% | 498.73M▲ 171.5% | 411.23M▼ 17.5% | 555.29M▲ 35.0% | 374.51M▼ 32.6% | 415.84M▲ 11.0% | 210.54M▲ 0% |
| Equity Growth % | - | -143.75% | 591.15% | 33.27% | 171.46% | -17.54% | 35.03% | -32.56% | 11.04% | -97.33% |
| Book Value per Share | -0.37 | -0.91 | 5.94 | 5.36 | 10.78 | 7.88 | 9.54 | 5.63 | 5.16 | 2.28 |
| Total Shareholders' Equity | -11.52M | -28.07M | 137.86M | 183.72M | 498.73M | 411.23M | 555.29M | 374.51M | 415.84M | 210.54M |
| Common Stock | 5K | 5K | 32K | 37K | 47K | 47K | 57K | 61K | 77K | 79K |
| Retained Earnings | -9.23M | -28.93M | -59.77M | -112.3M | -193.17M | -311.2M | -485.49M | -701.28M | -948.58M | -1.19B |
| Treasury Stock | -255K | -1.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.55M | -238K | -1.05M | -982K | -394K | -973K | 5.73M | 4.86M | 5.45M | 5.56M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
REPL Cash Flow Statement
Replimune Group, Inc. (REPL) cash flow — operating, investing & free cash flow history
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -7.08M | -16.01M | -25.38M | -60.55M | -61.39M | -82.18M | -128.05M | -185.47M | -192.25M | -192.25M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -126.28% | -58.47% | -138.6% | -1.38% | -33.87% | -55.82% | -44.84% | -3.66% | -213.26% |
| Net Income | -7.7M | -19.7M | -30.83M | -52.63M | -80.87M | -118.04M | -174.28M | -215.79M | -247.3M | -314.85M |
| Depreciation & Amortization | 122K | 109K | 148K | 533K | 1.71M | 2.15M | 2.45M | 2.65M | 3.5M | 3.98M |
| Stock-Based Compensation | 208K | 812K | 2.73M | 7.74M | 11.79M | 24.25M | 28.13M | 34.13M | 35.04M | 32.43M |
| Deferred Taxes | 0 | 849K | 3.74M | -945K | 0 | 0 | 38K | 0 | 0 | 0 |
| Other Non-Cash Items | 150K | 26K | 93K | 156K | 2.47M | 2.22M | 494K | -11.94M | -7.58M | -1.81M |
| Working Capital Changes | 147K | 1.89M | -1.25M | -15.41M | 3.51M | 7.24M | 15.12M | 5.48M | 24.08M | 2.34M |
| Change in Receivables | -1.21M | -767K | -255K | -628K | 325K | -247K | -61K | -1.92M | 1.3M | 354K |
| Change in Inventory | 0 | 0 | 255K | 628K | 0 | 247K | 61K | 0 | 0 | 0 |
| Change in Payables | 203K | 1.6M | 120K | -3.82M | -1.03M | 1.12M | 1.98M | -2.79M | 9.94M | -654K |
| Cash from Investing | -238K | -44.05M | -65.94M | -5.23M | -188.78M | -1.81M | -142.5M | 97.2M | -23.8M | 216.64M |
| Capital Expenditures | -238K | -136K | -2.6M | -6.54M | -2.39M | -2.34M | -2.27M | -5.66M | -6.69M | -5.35M |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | -1.31K | 0 | -530 | 140.23K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -43.91M | -63.34M | 1.31K | 0 | 530 | -140.23K | 0 | 0 | 0 |
| Cash from Financing | 15M | 54.75M | 101.39M | 100.17M | 372.46M | 6.6M | 311.3M | 16.28M | 252.4M | 10.48M |
| Debt Issued (Net) | 0 | 0 | 0 | 9.94M | -10.14M | -264K | 27.79M | 14.52M | -599K | -701K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 509K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | -1.95M | 28.34M | 96.5M | 0 | 96.22M | 0 | 97.27M | 97.03M |
| Net Change in Cash | 6.27M▲ 0% | -3.01M▼ 148.1% | 9.23M▲ 406.5% | 34.25M▲ 271.1% | 123.02M▲ 259.2% | -76.57M▼ 162.2% | 40.64M▲ 153.1% | -72.07M▼ 277.3% | 36.66M▲ 150.9% | -49.29M▲ 0% |
| Free Cash Flow | -7.32M▲ 0% | -16.15M▼ 120.8% | -27.98M▼ 73.2% | -67.09M▼ 139.8% | -63.78M▲ 4.9% | -84.52M▼ 32.5% | -130.32M▼ 54.2% | -191.13M▼ 46.7% | -198.94M▼ 4.1% | -283.27M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | - | -120.78% | -73.24% | -139.8% | 4.93% | -32.51% | -54.2% | -46.66% | -4.09% | -47.55% |
| FCF per Share | -0.24 | -0.52 | -1.21 | -1.96 | -1.38 | -1.62 | -2.24 | -2.87 | -2.47 | -2.47 |
| FCF Conversion (FCF/Net Income) | 0.92x | 0.81x | 0.82x | 1.15x | 0.76x | 0.70x | 0.73x | 0.86x | 0.78x | 0.90x |
| Interest Paid | 0 | 0 | 0 | 0 | 636K | 0 | 0 | 3.04M | 4.2M | 3.17M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 55K | 0 | 300K | 105K | 0 |
REPL Key Ratios
Replimune Group, Inc. (REPL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -56.17% | -32.73% | -23.7% | -25.94% | -36.06% | -46.42% | -62.58% | -149.55% |
| Return on Invested Capital (ROIC) | - | -63.53% | -29.61% | -24.08% | -26.5% | -32.89% | -41.66% | -51.85% | -51.85% |
| Debt / Equity | - | 0.05x | 0.23x | 0.07x | 0.08x | 0.11x | 0.20x | 0.18x | 0.18x |
| Interest Coverage | - | - | -29.29x | -27.05x | -54.65x | -42.57x | -35.25x | -33.15x | -48.62x |
| FCF Conversion | 0.81x | 0.82x | 1.15x | 0.76x | 0.70x | 0.73x | 0.86x | 0.78x | 0.90x |
REPL SEC Filings & Documents
Replimune Group, Inc. (REPL) SEC filings — annual & quarterly reports (10-K, 10-Q)
REPL Frequently Asked Questions
Replimune Group, Inc. (REPL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Replimune Group, Inc. (REPL) grew revenue by 0.0% over the past year. Growth has been modest.
Replimune Group, Inc. (REPL) reported a net loss of $314.9M for fiscal year 2025.
Dividend & Returns
Replimune Group, Inc. (REPL) has a return on equity (ROE) of -62.6%. Negative ROE indicates the company is unprofitable.
Replimune Group, Inc. (REPL) had negative free cash flow of $283.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More REPL
Replimune Group, Inc. (REPL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates